RxDoctor Payments Data

Casey Nolan

Adult Health · New York, NYNPI 1548931041

Payments from drug & device makers

$1,029in general payments, 2019–2025

Across 28 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$268
  • Alnylam Pharmaceuticals Inc.$233
  • Pfizer$156
  • Novartis$108
  • Amgen$100
  • Boehringer Ingelheim$89
  • plus $75 from 2 others

What the payments were for

  • Food & beverage$1,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,029 in reported general payments places this provider in the 65th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$63,540
Medicare patients
368
Services billed
1,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban269$332,187
EntrestoSacubitril/Valsartan103$147,677
FarxigaDapagliflozin Propanediol75$79,971
Repatha SureclickEvolocumab59$52,493
XareltoRivaroxaban37$42,680
MounjaroTirzepatide33$33,537
JardianceEmpagliflozin27$31,282
WegovySemaglutide20$26,689
OzempicSemaglutide18$24,288
DapagliflozinDapagliflozin Propanediol14$13,057
Repatha PushtronexEvolocumab13$11,215
Atorvastatin Calcium493$5,658
Metoprolol Succinate318$5,174
Rosuvastatin Calcium246$3,309
Ezetimibe82$1,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$332,187269 claims
NovartisEntresto$108$147,677103 claims
Boehringer IngelheimJardiance$89$31,28227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →